Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Sales and Divestitures: 2022-2024

Historic Gains from Sales and Divestitures for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $323,031.

  • Taysha Gene Therapies' Gains from Sales and Divestitures rose 285.79% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 285.79%. This contributed to the annual value of $323,031 for FY2024, which is 42.00% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Gains from Sales and Divestitures of $323,031 as of FY2024, which was down 42.00% from $556,989 recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Gains from Sales and Divestitures ranged from a high of $628,921 in FY2022 and a low of $323,031 during FY2024.
  • Its 3-year average for Gains from Sales and Divestitures is $502,980, with a median of $556,989 in 2023.
  • Data for Taysha Gene Therapies' Gains from Sales and Divestitures shows a maximum YoY plummeted of 42.00% (in 2024) over the last 5 years.
  • Over the past 3 years, Taysha Gene Therapies' Gains from Sales and Divestitures (Yearly) stood at $628,921 in 2022, then fell by 11.44% to $556,989 in 2023, then crashed by 42.00% to $323,031 in 2024.